Cargando…

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus

Diabetic nephropathy is one of three major complications of diabetes mellitus, often leading to chronic renal failure requiring dialysis. Recently developed dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit renoprotective effects in addition to antihyperglycemic effects. In this study, we retros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esaki, Hiroki, Tachi, Tomoya, Goto, Chitoshi, Sugita, Ikuto, Kanematsu, Yuta, Yoshida, Aki, Saito, Kosuke, Noguchi, Yoshihiro, Ohno, Yuki, Aoyama, Satoshi, Yasuda, Masahiro, Mizui, Takashi, Yamamura, Masumi, Teramachi, Hitomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694778/ https://www.ncbi.nlm.nih.gov/pubmed/29187821 http://dx.doi.org/10.3389/fphar.2017.00835

Ejemplares similares

The adoption of generic drugs by a hospital: effects on drug dispensation among community pharmacies
por: Tachi, Tomoya, et al.
Publicado: (2018)

A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study
por: Noguchi, Yoshihiro, et al.
Publicado: (2022)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

The Effect of Quality of Life on Medication Compliance Among Dialysis Patients
por: Nagasawa, Hiroyuki, et al.
Publicado: (2018)

The Relationship Between Dialysis Patients' Quality of Life and Caregivers' Quality of Life
por: Nagasawa, Hiroyuki, et al.
Publicado: (2018)

Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost
por: Teramachi, Hitomi, et al.
Publicado: (2014)

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

Effects of the number of drugs used on the prevalence of adverse drug reactions in children
por: Sugioka, Mayuko, et al.
Publicado: (2020)

The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients
por: Tachi, Tomoya, et al.
Publicado: (2015)

The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis
por: Tachi, Tomoya, et al.
Publicado: (2016)

Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer
por: Tanaka, Kazuhide, et al.
Publicado: (2018)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio
por: Noguchi, Yoshihiro, et al.
Publicado: (2020)

Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure
por: Arruda-Junior, Daniel F., et al.
Publicado: (2016)

Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
por: Noguchi, Yoshihiro, et al.
Publicado: (2020)

Review of Statistical Methodologies for Detecting Drug–Drug Interactions Using Spontaneous Reporting Systems
por: Noguchi, Yoshihiro, et al.
Publicado: (2019)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Verification of the “Upward Variation in the Reporting Odds Ratio Scores” to Detect the Signals of Drug–Drug Interactions
por: Noguchi, Yoshihiro, et al.
Publicado: (2021)

Angioedema Caused by Drugs That Prevent the Degradation of Vasoactive Peptides: A Pharmacovigilance Database Study
por: Noguchi, Yoshihiro, et al.
Publicado: (2021)

Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor
por: Kodera, Ryo, et al.
Publicado: (2015)

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
por: Uchida, Takahiro, et al.
Publicado: (2017)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
por: Qiu, Dan-Dan, et al.
Publicado: (2018)

Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system
por: Toyoshima, Manabu, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
por: Takedomi, Hironobu, et al.
Publicado: (2022)

Factors Influencing Medicine Use Behavior in Adolescents in Japan Using a Bayesian Network Analysis
por: Sakai, Chihiro, et al.
Publicado: (2019)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bjfc2i5snvi687rhf3bd07kqgi